Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study - Context Therapeuti

Context Therapeutics reports 29% ORR in evaluable ovarian cancer patients treated with CTIM-76, with favorable safety data.

Raccontata dabenzinga.com